Search

Displaying results 2501 - 2510 of 8195 in total
  1. Drug

    DA-697b

    go.drugbank.com/drugs/DB06001
    Experimental

    DA-967b is an investigational antiplatelet agent that inhibits collagen and ristocetin-mediated platelet activation.

  2. Drug

    Amfecloral

    go.drugbank.com/drugs/DB08924
    Experimental

    This would produce an effect similar to the amphetamine/barbiturate combinations previously used in psychiatric medications. … For a short period of time, it was available under the brand Acutran and indicated as an appetite suppressant, but this product no longer exists.

  3. Drug

    Methyl undecenoyl leucinate

    go.drugbank.com/drugs/DB11272
    Approved

    Methyl undecenoyl leucinate is an active ingredient in whitening creams. … It is an α-MSH antagonist that inhibits melanin synthesis and tyrosinase activity and reduces expression of various melanogenic genes.

  4. Drug

    Melphalan flufenamide

    go.drugbank.com/drugs/DB16627
    ApprovedWithdrawn

    Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan. Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that...

  5. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas. This drug is made up of paramagnetic manganese (II) ions combined wi...

  6. Drug

    Ifosfamide

    go.drugbank.com/drugs/DB01181
    ApprovedInvestigational

    It is active as an alkylating agent and an immunosuppressive agent.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  7. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    The average molecular mass of lipegfilgrastim comprises 18,798 Da for [DB00099], 203 Da for GalNAc, 338 Da for glycylsialic acid and approximately 20,000 Da for PEG [L2449]. … It is used as an alternate to [DB00019] for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia.

  8. Drug

    Zansecimab

    go.drugbank.com/drugs/DB16389
    Investigational

    Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).

  9. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. … Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates